Online citations, reference lists, and bibliographies.

Are Curcuminoids Effective C-reactive Protein-lowering Agents In Clinical Practice? Evidence From A Meta-analysis.

A. Sahebkar
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease (CVD). In this context, C-reactive protein (CRP) has been identified as a strong predictor and independent risk factor of CVD. Curcuminoids are multifunctional natural product with promising cardioprotective and anti-inflammatory properties. Curcuminoids have been suggested to lower circulating levels of CRP, but clinical findings have not been consistent. OBJECTIVES To pool the published results of clinical trials on the impact of supplementation with curcuminoids on circulating levels of CRP. METHODS PubMed/MEDLINE and SCOPUS databases were searched for clinical trials reporting circulating CRP changes in individuals receiving curcuminoids. Effect sizes with 95% confidence intervals (CI) were calculated using a random-effects model. Inter-study heterogeneity was assessed using Cochran's Q and I(2) tests. Sensitivity analyses were conducted using leave-one-out method. RESULTS Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta-analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: -6.44 mg/L; 95% CI: -10.77 - -2.11; p = 0.004). This significant effect was maintained in subgroups of trials that used bioavailability-improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. CONCLUSIONS Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well-designed and long-term trials are warranted to verify this effect of curcuminoids.
This paper references
10.1161/01.CIR.100.1.96
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?
W. Lagrand (1999)
10.1056/NEJM200010193431602
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
B. Lindahl (2000)
10.1016/j.jvs.2005.01.030
C-reactive protein levels and outcomes after statin therapy.
P. Ridker (2005)
10.1017/S0007114511006544
Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial.
Y. Panahi (2012)
10.4065/81.12.1579
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
R. Goldberg (2006)
10.1089/ars.2007.1769
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials.
A. Strimpakos (2008)
Cardiovascular protection by curcumin: molecular aspects.
Georgia Kapakos (2012)
10.1056/NEJMoa0800742
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
J. Kastelein (2008)
Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog.
R. Engler (1983)
10.1161/01.ATV.0000256469.06782.d5
Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level
A. Hiuge (2007)
10.1007/s10620-005-3032-8
Curcumin Therapy in Inflammatory Bowel Disease: A Pilot Study
P. Holt (2005)
10.1016/S0009-9120(00)00186-7
High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy.
H. Yu (2000)
10.1258/acb.2012.012040
A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications
Y. Panahi (2012)
10.1161/01.CIR.0000148955.19792.8D
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
A. Taylor (2004)
10.1042/BJ20020045
Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions.
Tao Fu (2002)
10.3923/PJN.2008.561.565
Investigation of the Effects of Statin Therapy on Serum Vitamin E Status in Patients with Dyslipidemia
Majid Ghayour-Mobarhan (2008)
10.1021/np1007262
Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation.
J. Cuomo (2011)
10.1124/jpet.108.137455
Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease
A. N. Begum (2008)
10.1016/j.nut.2012.02.006
Curcumin attenuates rat thoracic aortic aneurysm formation by inhibition of the c-Jun N-terminal kinase pathway and apoptosis.
J. Fan (2012)
10.1186/1471-2288-5-13
Estimating the mean and variance from the median, range, and the size of a sample
Stela Pudar Hozo (2005)
10.1007/s13346-011-0041-3
Protective effects of nanoparticulate coenzyme Q10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications
Venkat Ratnam Devadasu (2011)
Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines.
A. Mackiewicz (1991)
10.1186/1475-2891-11-79
Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people
R. DiSilvestro (2012)
10.2174/157016108785909733
The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.
E. Nakou (2008)
10.1056/NEJM199901143400207
Atherosclerosis is an inflammatory disease.
R. Ross (1999)
10.1007/s10557-010-6279-z
Phosphatidylcholine-Rich Nanoliposomes: Potential Tools for Serum C-Reactive Protein Reduction?
Amir Hossein Sahebkar (2010)
10.1016/J.BCP.2005.04.043
Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
S. Shishodia (2005)
10.1056/NEJMoa0807646
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
P. Ridker (2008)
10.1016/j.amjcard.2012.02.043
Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting.
W. Wongcharoen (2012)
10.1016/J.FREERADBIOMED.2005.09.008
Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups.
Wei-feng Chen (2006)
10.1002/ptr.4715
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.
A. Mohammadi (2013)
10.2174/138161211798764843
Pathophysiology of atherosclerosis: the role of inflammation.
D. Tousoulis (2011)
10.1016/j.jaad.2011.04.022
High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus.
N. Chainani-Wu (2012)
10.1021/MP700113R
Bioavailability of curcumin: problems and promises.
P. Anand (2007)
10.1002/mnfr.201100818
Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration.
Dilek Coban (2012)
10.1007/s00280-006-0355-x
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine
T. H. Marczylo (2006)
10.1016/0197-2456(95)00134-4
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
A. Jadad (1996)
Antioxidative effect of curcumin ( Curcuma longa ) on lipid peroxidation and lipofuscinogenesis in submandibular gland of D-galactose- induced aging male mice
P. P. Sarvalkar (2011)
10.1016/J.JSS.2004.11.009
Inhibition of NFκB Activation with Curcumin Attenuates Plasma Inflammatory Cytokines Surge and Cardiomyocytic Apoptosis Following Cardiac Ischemia/Reperfusion1
Chi-Hsiao Yeh (2005)
10.1002/biof.1066
Curcumin in inflammatory diseases
A. Shehzad (2013)
10.1080/07315724.2009.10719782
Effect of Exclusion Diet with Nutraceutical Therapy in Juvenile Crohn's Disease
A. Slonim (2009)
10.2174/2212796810903010060
Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
F. Montecucco (2009)
10.1021/jf9024807
Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers.
V. Gota (2010)
10.1097/MCO.0b013e32834bfe94
Curcuma as a functional food in the control of cancer and inflammation
M. Schaffer (2011)
10.1016/j.amjcard.2008.10.025
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
A. Goldberg (2009)
10.22038/IJBMS.2012.4935
Evaluation of Curcumin Effects on Post-Operative Peritoneal Adhesion in Rats
V. Jomezadeh (2012)
10.1056/NEJM199704033361401
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P. Ridker (1997)
10.1002/ptr.4952
Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals.
A. Sahebkar (2013)
10.4065/81.9.1177
Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial.
T. Pearson (2006)
10.1056/NEJM199408183310701
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
G. Liuzzo (1994)
10.7556/JAOA.2005.105.9.409
C-reactive protein: a new risk assessment tool for cardiovascular disease.
M. Clearfield (2005)
10.1016/S0891-5849(00)00294-X
Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress.
R. Motterlini (2000)
10.1016/S0735-1097(98)00136-3
C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy
D. Morrow (1998)
10.1007/978-0-387-46401-5_3
Antioxidant and anti-inflammatory properties of curcumin.
V. Menon (2007)
10.1146/annurev.nutr.012809.104755
Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals.
B. Aggarwal (2010)
10.1016/J.AMJCARD.2005.11.039
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
H. Bays (2006)
10.1002/ardp.200900319
Curcumin in Cancer Chemoprevention: Molecular Targets, Pharmacokinetics, Bioavailability, and Clinical Trials
A. Shehzad (2010)
10.1016/0952-7915(95)80029-8
Structure and function of the pentraxins.
H. Gewurz (1995)
10.1016/j.atherosclerosis.2008.09.027
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
P. Jones (2009)
10.1093/cvr/28.4.437
The complement system in myocardial ischaemia/reperfusion injury.
K. Kilgore (1994)
10.1002/mnfr.201100440
Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism.
Su-kyung Shin (2011)
10.1172/JCI32865
Curcumin prevents and reverses murine cardiac hypertrophy.
H. Li (2008)
10.1007/s11130-012-0325-x
Influence of Red Pepper Spice and Turmeric on Inflammation and Oxidative Stress Biomarkers in Overweight Females: A Metabolomics Approach
David C Nieman (2012)
10.1084/jem.123.2.365
THE LIVER AS THE SITE OF C-REACTIVE PROTEIN FORMATION
J. Hurlimann (1966)
10.1016/j.ijcard.2009.01.073
The protective role of curcumin in cardiovascular diseases.
W. Wongcharoen (2009)
10.1007/s11883-009-0075-x
Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment
P. Joshi (2010)
10.4103/0253-7613.91871
Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats
Agadihiremath Vishwanatha Swamy (2012)
10.1007/s00394-011-0188-1
New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases
A. Shehzad (2011)
10.1177/1074248408329608
Currying the Heart: Curcumin and Cardioprotection
Geetika Srivastava (2009)
10.1111/J.1527-3466.2006.00033.X
C-reactive protein (CRP)-lowering agents.
K. Prasad (2006)
10.1093/AJHP/61.16.1676
HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein.
K. Chan (2004)
10.1017/S0007114509993667
Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies.
Jenny Epstein (2010)
10.1007/BF00420910
Protective role of curcumin against isoproterenol induced myocardial infarction in rats
C. Nirmala (2004)
10.1016/j.ijsu.2010.02.007
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
D. Moher (2010)
10.1016/j.fertnstert.2010.07.1071
Molecular mechanisms for curcumin benefits against ischemic injury.
A. Sahebkar (2010)
10.1055/S-2006-957450
Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.
G. Shoba (1998)



This paper is referenced by
10.1097/MD.0000000000005165
Impact of different types of tree nut, peanut, and soy nut consumption on serum C-reactive protein (CRP)
Mohsen Mazidi (2016)
10.1111/bcp.12905
Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms.
A. Sahebkar (2016)
10.1016/j.phrs.2018.06.007
The clinical efficacy of curcumin‐containing nutraceuticals: An overview of systematic reviews
E. Pagano (2018)
10.1002/jcb.25892
Ocular Effects of Sulfur Mustard and Therapeutic Approaches.
Y. Panahi (2017)
10.1016/j.phrs.2016.07.004
Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials.
G. Derosa (2016)
10.1007/112_2016_3
Curcumin as a MicroRNA Regulator in Cancer: A Review.
Amir Abbas Momtazi (2016)
10.1016/j.biopha.2017.01.078
Curcumin and treatment of melanoma: The potential role of microRNAs.
D. Lelli (2017)
10.1002/jcp.26249
Curcumin, hemostasis, thrombosis, and coagulation.
F. Keihanian (2018)
10.1002/ijc.30224
Curcumin: A new candidate for melanoma therapy?
H. Mirzaei (2016)
10.1177/1074248413511691
A Systematic Review and Meta-Analysis of the Effects of Pycnogenol on Plasma Lipids
Amir Hossein Sahebkar (2014)
10.1016/j.biopha.2016.11.098
Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies.
Hamed Mirzaei (2017)
10.1002/jcp.27362
Curcumin nanofibers for the purpose of wound healing.
Narges Fereydouni (2019)
10.1016/j.phrs.2016.12.037
Curcumin: A potentially powerful tool to reverse cisplatin‐induced toxicity
R. Rezaee (2017)
10.1097/FJC.0000000000000406
Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Y. Panahi (2016)
10.1002/ptr.5640
Effects of Turmeric (Curcuma longa) on Skin Health: A Systematic Review of the Clinical Evidence.
A. Vaughn (2016)
10.1002/ptr.6571
Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial.
S. Asadi (2019)
10.1016/j.jnutbio.2018.12.005
Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent.
A. Mohammadi (2019)
10.1007/s00580-015-2217-6
Clinical evaluation of the effects of supplementation with curcuminoids on serum fetuin-B concentrations in obese subjects
Maryam Saberi Karimian (2015)
10.1016/j.jad.2016.09.047
Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study.
Adrian L Lopresti (2017)
10.1016/j.canlet.2017.03.020
Naturally occurring anti-cancer agents targeting EZH2.
Fahimeh Shahabipour (2017)
10.1002/ptr.5905
Curcuminoids Lower Plasma Leptin Concentrations: A Meta‐analysis
Stephen L. Atkin (2017)
10.22127/rjp.2018.80375
Efficacy of Prasaplai for Treatment of Primary Dysmenorrhea: a Meta-Analysis
Wiraphol Phimarn (2019)
10.1002/jcp.26620
The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K/AKT pathway.
Leila Hamzehzadeh (2018)
10.1080/10408398.2019.1653260
Curcumin for depression: a meta-analysis
Laura Fusar-Poli (2019)
10.1016/j.phrs.2017.02.008
Effects of curcumin on HDL functionality
S. Ganjali (2017)
10.1016/j.clnu.2013.09.012
A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels.
A. Sahebkar (2014)
10.1016/j.plipres.2015.08.003
Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials.
Gianna Ferretti (2015)
10.1002/ptr.5524
The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials.
Dalia Al-Karawi (2016)
10.1186/s40795-017-0207-6
Impact of vitamin D supplementation on C-reactive protein; a systematic review and meta-analysis of randomized controlled trials
M. Mazidi (2018)
10.1055/s-0042-109394
Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial.
A. Khonche (2016)
10.1002/ptr.5174
Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial.
Y. Panahi (2014)
10.1016/j.jash.2017.12.002
Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials.
A. Sahebkar (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar